We have previously shown that siRNA-mediated GHR targeting in cultured melanoma cells markedly sensitize them to cisplatin, doxorubicin, paclitaxel or vemurafenib effects by attenuating ABCB, ABCG, and ABCC type multidrug transporters and provided a new mechanistic rationale of GH-mediated therapy refractoriness (28). This evidence concerns the gene GH1 and melanoma.